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miR-638 is a new biomarker for outcome prediction
of non-small cell lung cancer patients receiving
chemotherapy
Fang Wang1,2, Jian-fang Lou1,2, Yan Cao1,2, Xin-hui Shi1,2, Peng Wang1,2, Jian Xu1,2, Er-fu Xie1,2, Ting Xu1,2,
Rui-hong Sun1,2, Jian-yu Rao3, Pu-wen Huang4, Shi-yang Pan1,2 and Hong Wang5
MicroRNAs (miRNAs), a class of small non-coding RNAs, mediate gene expression by either cleaving target mRNAs or inhibiting
their translation. They have key roles in the tumorigenesis of several cancers, including non-small cell lung cancer (NSCLC). The
aim of this study was to investigate the clinical significance of miR-638 in the evaluation of NSCLC patient prognosis in
response to chemotherapy. First, we detected miR-638 expression levels in vitro in the culture supernatants of the NSCLC cell
line SPC-A1 treated with cisplatin, as well as the apoptosis rates of SPC-A1. Second, serum miR-638 expression levels were
detected in vivo by using nude mice xenograft models bearing SPC-A1 with and without cisplatin treatment. In the clinic, the
serum miR-638 levels of 200 cases of NSCLC patients before and after chemotherapy were determined by quantitative real-time
PCR, and the associations of clinicopathological features with miR-638 expression patterns after chemotherapy were analyzed.
Our data helped in demonstrating that cisplatin induced apoptosis of the SPC-A1 cells in a dose- and time-dependent manner
accompanied by increased miR-638 expression levels in the culture supernatants. In vivo data further revealed that cisplatin
induced miR-638 upregulation in the serum derived from mice xenograft models, and in NSCLC patient sera, miR-638
expression patterns after chemotherapy significantly correlated with lymph node metastasis. Moreover, survival analyses revealed
that patients who had increased miR-638 levels after chemotherapy showed significantly longer survival time than those who had
decreased miR-638 levels. Our findings suggest that serum miR-638 levels are associated with the survival of NSCLC patients
and may be considered a potential independent predictor for NSCLC prognosis.
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INTRODUCTION
Lung cancer is characterized with a high incidence and
poor prognosis, and it is the leading cause of cancer-related
death worldwide, with a dismal 5-year survival rate of
less than 15%.1–3 The most common lung cancer variant is
non-small cell lung cancer (NSCLC), which accounts for
~ 85% of lung cancer cases. Chemotherapy is the most
frequent treatment for NSCLC and helps to improve
the life quality and prolong the survival of patients.4
However, further work is required to monitor NSCLC patient
responses to chemotherapy and thereby improving the patient
outcomes.
Mature, biologically active microRNAs (miRNAs) are endo-
genous short non-coding RNAs and are known to have
essential roles in the regulation of numerous biological
processes, such as development, differentiation, proliferation
and apoptosis.5–7 They achieve this by interfering with the
translation or stability of genes by binding the 3′ UTR of target
mRNAs at the posttranscriptional level.8 Over the past few
decades, the number of identified miRNAs has continued to
grow, and our knowledge of miRNA biology has increased
accordingly.9 On the basis of their role in cancer pathology and
the types of gene that they target, miRNAs can be divided into
oncogenes and tumor suppressor genes. miR-638 has been
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reported to be downregulated in several types of cancer, such as
gastric cancer,10 leukemia11 and basal cell carcinoma,12 and
may therefore function as a tumor suppressor gene.
Previously, we successfully prepared a monoclonal antibody
named NJ001 that is specific to NSCLC.13 In this earlier study,
the lung cancer cell line SPC-A1 was treated with NJ001 in vitro
for different periods of time and expression microarray
analyses were then performed with the extracted RNA. We
found that miR-638 exhibited the most significant time-
dependent differential expression in response to NJ001 (GEO
accession number: GSE51947). Furthermore, recent studies
have revealed that miR-638 is aberrantly expressed in several
cancers,10,14,15 suggesting that it may be involved in cancer
development and progression. Thus, we next focused on
exploring the potential clinical application of miR-638. Speci-
fically, the aim of this study was to explore the usefulness of
serum miR-638 detection for predicting the NSCLC outcome.
MATERIALS AND METHODS
Cell culture and in vitro experiments
The SPC-A1 cell line was purchased from the type culture collection of
the Chinese Academy of Sciences, Shanghai, China, and was proven to
be uncontaminated by bacterium or mycoplasma by the European
Collection of Cell Cultures using mass spectrometry. The cells were
grown in RPMI1640 medium supplemented with 10% fetal bovine
serum, 1% penicillin and 1% streptomycin at 37 °C and 5% CO2. For
in vitro experiments, SPC-A1 cells in the exponential growth phase
were seeded in six-well plates (2× 106 per well) and treated with
different concentrations (0.5, 2.5 and 5 μg ml− 1) of cisplatin or
complete RPMI1640 medium alone (as the control group) and
incubated at 37 °C and 5% CO2 for 24, 48 or 72 h. Cultured
supernatants were then harvested for miR-638 detection. Each time
point was set in triplicates, and the whole experiment was repeated
three times.
Detection of apoptosis
The apoptosis rates of the SPC-A1 cells were determined by flow
cytometry. Approximately 1× 105 cells were collected for apoptosis
rate detection by flow cytometry. Cells were re-suspended and stained
with Annexin V-FITC and propidium iodide (Annexin V-FITC
Apoptosis Detection Kit, BD Biosciences, Franklin, NJ, USA) accord-
ing to the manufacturer’s instruction. FACS analysis was then carried
out on a FACScan cytometer (BD Biosciences).
In vivo tumor establishment, cisplatin treatment and
serum isolation
Experimental nude mice were purchased from Slack Experimental
Animal Co. in Shanghai with Certification No.: SCXK (Shanghai,
China) 2009-0002 and SPF level status. The mice were housed in an
SPF animal facility in the Experimental Animal Center of Jiangsu
Province. In vivo experiments were carried out using nude mice aged
6 weeks. The xenograft models were established by subcutaneous
injection of 2× 106 SPC-A1 cells, and non-injected mice (n= 5) served
as a control group. After 2 weeks, when tumor tubercles were
significantly observed, the mice were divided into three groups. The
first group was injected with cisplatin at a dose of 0.5 μg per 100 μl via
the caudal vein (n= 6); the second group received an equal volume of
normal saline (NS) (n= 5) and served as a negative control group; and
the remaining xenograft models were not treated with either cisplatin
or NS (n= 5). The treatments were performed three times every other
day. Blood was collected the day after the last administration and
centrifuged at a speed of 16 000 g for 10min at room temperature to
isolate serum after coagulation.
Patients and serum specimens
Clinical samples were collected from a cohort of 200 cases of NSCLC
patients during their hospitalization from July 2009 to March 2013 at
the First Affiliated Hospital of Nanjing Medical University, China.
Blood was collected before and after chemotherapy with patients’
informed consent. Serum was then separated from whole blood by
centrifugation at 2500 g for 10min, followed by 16 000 g for 10min to
completely remove cell debris, and then stored at − 70 °C until needed
for use.
RNA extraction and quantitative RT–PCR
Total RNA was extracted using the miRNeasy mini kit (QIAgen,
Valencia, CA, USA) according to the manufacturer’s protocol, with
cel-miR-39 (59-ucaccggguguaaaucagcuug-39; final concentration:
10− 5 pmol ml− 1) (Applied Biosystems, Foster City, CA, USA) added
as an internal control. RNA concentration and quality were validated
by using a UV spectrophotometer at 260 and 280 nm. Quantitative
PCR with reverse transcription (RT–PCR) was used to detect miR-638
expression levels. For reverse transcription, 9.16 μl RNA was used in
each reaction and mixed with 5.84 μl reverse transcription reagents
(Applied Biosystems), including stem-loop reverse transcription pri-
mers, according to the manufacturer’s instructions. The reverse
transcription reactions were performed at 16 °C for 30min, 42 °C
for 30min, 85 °C for 5 min and then maintained at 4 °C. Following
this, real-time PCR was conducted at 95 °C for 10min, followed by
95 °C for 15 s with 45 cycles and 60 °C for 1min in an ABI 7500
Real-Time PCR system. miR-638 expression levels are presented in
terms of fold change normalized to cel-miR-39 expression using
the formula 2−ΔΔCt in which ΔΔCt= (Ct miR-638−Ct miR-39)treated−
(Ct miR-638−Ct miR-39)untreated.
Statistical analysis
Statistical analyses were performed using Graphpad Prism 5.0 (San
Diego, CA, USA) and SPSS 16.0 software (Chicago, IL, USA). A
survival analysis was performed with the Kaplan–Meier method, and
the log-rank test was used to compare survival times between groups.
A P-value o0.05 was considered statistically significant.
RESULTS
Cisplatin induces apoptosis of SPC-A1 cells
To evaluate the effect of cisplatin on SPC-A1 apoptosis, SPC-
A1 cells were treated with different doses of cisplatin for
different periods of time. The apoptosis rates for 24, 48 and
72 h were then determined after treatment with/without
cisplatin using flow cytometry. The apoptosis rates of the
SPC-A1 cells cultured for 24, 48 and 72 h with cisplatin
at a concentration of either 2.5 or 5 μgml− 1 were signi-
ficantly greater than those of paired untreated control groups
(Figures 1a and b), and these apoptosis rates increased more
markedly with prolonged exposure to higher concentrations of
cisplatin. These data suggest that cisplatin induces apoptosis of
SPC-A1 cells in a dose- and time-dependent manner.
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Cisplatin treatment induces miR-638 expression in a
time- and dose-dependent manner in SPC-A1 cultured
supernatants
Quantitative RT–PCR (qRT–PCR) was used to detect the
expression levels of miR-638 in the culture supernatants of
SPC-A1 cells treated with cisplatin. The results showed that the
miR-638 expression levels in the SPC-A1-cultured supernatants
were more than four-fold higher after being treated with
cisplatin for 72 h at a concentration of 2.5 μgml− 1 when
compared with expression levels in the untreated control group
(Figure 2a). Furthermore, treatment of SPC-A1 cells with either
2.5 or 5.0 μgml− 1 cisplatin both resulted in a significant
increase in miR-638 expression levels in the supernatants
compared with that of the control group. Moreover, it was
observed that the miR-638 levels in supernatants also increased
in a time-dependent manner when 5.0 μgml− 1 cisplatin was
used for treatment for different periods of time (24–72 h)
(Figure 2b).
Cisplatin treatment in vivo up-regulates miR-638
expression levels
To address whether cisplatin treatment affects miR-638 expres-
sion in vivo, we analyzed miR-638 expression levels in sera of
nude mice SPC-A1 xenograft models with and without
cisplatin treatment by using qRT–PCR. A marked increase in
miR-638 expression was observed in the sera of the SPC-A1
lung carcinoma group with cisplatin administration compared
with the lung carcinoma group without any treatment, the lung
carcinoma group with NS treatment or the blank control
group. However, no significant difference in serum miR-638
expression was observed in either of the two lung carcinoma
groups without any treatment, the lung carcinoma group with
NS treatment or the blank control group. An increase in serum
miR-638 expression levels was observed as early as 24 h post-
treatment with cisplatin. These data suggest that cisplatin
administration in SPC-A1 xenograft models induces upregula-
tion of miR-638 expression as early as 24 h post-treatment
(Figure 3).
Associations between clinicopathological features and
serum miR-638 expression patterns
To further explore the relationship between serum miR-638
expression and the clinicopathological features of NSCLC, the
correlation between serum miR-638 expression patterns after
chemotherapy and clinicopathological characteristics was
evaluated. The data presented in Table 1 show that the
upregulation of miR-638 in serum was significantly correlated
with a lower rate of lymph node metastasis (P= 0.017);
Figure 1 Apoptosis rates of SPC-A1 cells following cisplatin
treatment. (a) Apoptosis rates of SPC-A1 cells at different time
points post treatment with different doses of cisplatin, as indicated,
were measured by flow cytometry. (b) The original flow cytometry
plot (*Po0.05).
Figure 2 Relative expression levels of miR-638 in SPC-A1 cultured
supernatants treated with cisplatin of 2.5 μgml−1 (a) and
5 μgml−1 (b). SPC-A1 cells were treated with different
concentrations (0.5, 2.5 and 5 μgml−1) of cisplatin for 24, 48
and 72 h, and miR-638 expression levels in SPC-A1 cultured
supernatants were determined by qRT–PCR. Data represent the
mean fold-change in miR-638 expression in three independent
groups relative to the untreated control group (*Po0.05).
miR-638 for predicting non-small cell lung cancer outcome
F Wang et al
3
Experimental & Molecular Medicine
however, there were no correlations between serum miR-638
expression and age, gender, smoking history or tumor-lymph
node-metastasis (TNM) stage (all P40.05). These results
suggest that elevated miR-638 expression may be inversely
correlated with NSCLC progression.
Correlation between miR-638 levels and NSCLC patients’
survival
As demonstrated, increased miR-638 expression levels were
observed in SPC-A1 culture supernatants in a time-dependant
manner after cisplatin treatment. To assess the prognostic value
of miR-638 in NSCLC patients receiving chemotherapy, we
determined its expression in serum before and after che-
motherapy derived from 200 cases of NSCLC patients in which
189 cases displayed miR-638 expression changes. We found
that serum miR-638 expression levels increased in 112 cases
(~60%) of the NSCLC patients after chemotherapy. After a 1-
year follow-up, we observed that the cumulative survival rate of
patients with increased miR-638 expression was 59.2% com-
pared with 47.5% of those with decreased miR-638 expression.
The survival data for the 183 cases of NSCLC with complete
records were analyzed by Kaplan–Meier survival curve and
compared with a log-rank test. This analysis revealed a
significant association between serum miR-638 levels and the
survival of NSCLC patients. Indeed, survival for patients with
increased miR-638 expression after chemotherapy was signifi-
cantly greater than that for patients with a decreased miR-638
expression (P= 0.0061, Figures 4 and 5). Moreover, Cox
proportional hazards regression analysis performed at the
univariate level indicated a significant correlation between
overall survival and serum miR-638 expression patterns (HR=
2.142; 95% CI, 1.130–4.060; P= 0.02) and regional lymph
node metastasis (HR= 6.035; 95% CI, 2.041–17.845; P= 0.001)
(Table 2). Clinicopathological features that were significantly
correlated with overall survival at the univariate level were then
analyzed by multivariate analysis, and the results demonstrated
that miR-638 (HR= 2.258; 95% CI, 1.031–3.456; P= 0.04) and
regional lymph node metastasis (HR= 3.196; 95% CI, 1.938–
15.869; P= 0.001) remained significant as independent prog-
nostic factors for overall survival rates (Table 2).
Dynamic changes in miR-638 levels during chemotherapy
To monitor the dynamics of serum miR-638 during chemo-
therapy, serum samples from NSCLC patients who received
several cycles of chemotherapy were collected after different
cycles of chemotherapy (Figure 6). For each individual, serum
samples were collected on the last day of each administration of
medication, and the relative fold change of 1 represented the
serum miR-638 expression level before chemotherapy. Figure 6
shows the dynamic changes in the serum miR-638 expression
levels of four representative patients after chemotherapy.
Patient A (Figure 6a) received six cycles of chemotherapy,
and CT scans showed that the tumor shrank significantly, with
decreased levels of tumor markers that were inversely asso-
ciated with serum miR-638 expression. Indeed, the serum
miR-638 level after the last administration of medication was
2.5-fold greater than that before chemotherapy, and the patient
was alive at 15 months of follow-up. Patient B (Figure 6b)
displayed a stable condition after three cycles of chemotherapy,
as determined by CT scans, along with decreased levels of
tumor markers, such as CEA, NSE and CYFRA21-1, in the
reference range and gradually increased serum miR-638
expression levels. At the time of our most recent follow-up,
27 months after treatment, patient B was still alive. By contrast,
patient C (Figure 6c) received four cycles of chemotherapy,
Figure 3 MiR-638 expression levels in serum of nude mice bearing
SPC-A1 xenografts. Mice bearing SPC-A1 xenografts were treated
with 5 μgml−1 of cisplatin (200 μl, n=6), NS (200 μl, n=5) or
received no treatment (n=5). The next day after the last drug
administration, serum was collected and miR-638 expression levels
were determined. The graph represents the mean serum miR-638
expression levels relative to the control group without SPC-A1 cells
(*Po0.05).
Table 1 Associations between serum miR-638 expression
patterns after chemotherapy and clinicopathological
characteristics in NSCLC patients (n=189)
miR-638 Upregulation miR-638 Downregulation P-value
Age
o60 55 37 0.887
460 57 40
Gender
Male 62 42 0.912
Female 50 35
Smoking history
Yes 51 36 0.741
No 61 41
TNM stage
I+II 39 26 0.881
III+IV 73 51
Lymph node metastasis
Yes 87 70 0.017*
No 25 7
*Po0.05.
miR-638 for predicting non-small cell lung cancer outcome
F Wang et al
4
Experimental & Molecular Medicine
during which CT scans determined that the patient’s condition
had deteriorated because of tumor metastasis. Throughout
treatment, the patient’s serum miR-638 levels were lower after
chemotherapy, and the patient lived for only 9 months after
cessation of treatment. Likewise, patient D (Figure 6d) received
three cycles of chemotherapy and displayed decreased serum
miR-638 levels together with tumor progression and metastasis,
as determined by CT scans. Additionally, serum levels of CEA,
CYFRA21-1 were observed to be higher than before che-
motherapy. In particular, serum miR-638 levels decreased
significantly after the second and third cycle of chemotherapy
in patient D. The relative fold change in serum miR-638 level
after the last cycle compared to the pre-treatment level was
0.06, trending to 0. The patient died 5 months after the final
diagnosis.
DISCUSSION
miRNAs have been shown to function in the regulation
of cell proliferation, apoptosis and cell transformation at a
posttranscriptional level.16–18 In lung cancer, studies have
shown that miRNAs play an important role in the develop-
ment of chemosensitivity or chemoresistance.19,20 Indeed,
miRNAs have been found to have a crucial role in the
regulation of tumor biological behavior, and their expression
patterns have been linked with tumor development. In the
field of oncology, miRNA detection has been confirmed to be
applicable in early diagnosis, prognosis and therapeutic
evaluation.21–24
Accumulating studies have revealed the dysregulation of
several miRNAs in NSCLC, suggesting that they play important
roles in tumorigenesis and the progression of NSCLC. For
instance, the downregulation of miR-497 in NSCLC promotes
cell proliferation and angiogenesis.25 miR-149 is also signifi-
cantly downregulated in NSCLC cells and is inversely corre-
lated with invasion through the inhibition of epithelial
mesenchymal transition by targeting FOXM1.26 Similarly,
miR-181b is markedly downregulated in NSCLC and signifi-
cantly correlates with tumor size, p-TNM/TNM stage, and the
status of lymph node metastasis.27 Moreover, miR-449a has
been shown to inhibit both cell migration and invasion by
directly targeting the c-Met gene in NSCLC, downregulation of
which has been associated with poor prognosis.28 Here, we
aimed to investigate the clinical significance of miR-638
in NSCLC.
A previous expression microarray analysis illustrated that
SPC-A1 cells treated with NJ001 exhibited the most
Figure 4 Expression levels of miR-638 in NSCLC patients before and after chemotherapy. Fold changes of serum miR-638 levels in
serum of each individual paired NSCLC patient sample before and after chemotherapy. Relative data are represented as log2 (fold change)
(after/before), in which a ‘Y’ value 41 was defined as an increase in miR-638 levels, whereas a value o–1 was defined as a decrease
in levels.
Figure 5 Kaplan–Meier survival curve for overall survival of NSCLC
patients (n=183). Kaplan–Meier analysis was performed to
evaluate the overall survival of NSCLC patients according to
miR-638 expression patterns after one cycle of first-line
chemotherapy, in which 109 patients had higher miR-638
expression levels, and 74 patients had lower miR-638 expression
levels.
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significantly increased expression of miR-638 in a time-
dependent manner. To further elucidate the potential role
and clinical value of miR-638 in NSCLC, we treated SPC-A1
cells with different concentrations of cisplatin for different
periods of time in vitro and measured the apoptosis rates and
the expression levels of miR-638 in culture supernatants. The
results showed that cisplatin induced SPC-A1 apoptosis in a
dose- and time-dependent manner. Importantly, this positively
correlated with a time-dependent increase in miR-638 expres-
sion in the culture supernatant when the concentration of
cisplatin was 2.5 or 5.0 μgml− 1. Moreover, miR-638 expres-
sion gradually increased following prolonged exposure times
and increased apoptosis rates, indicating a possible positive role
for miR-638 in apoptosis. Furthermore, in vivo tests demon-
strated that cisplatin-induced upregulation of miR-638 in the
sera of nude mice xenograft models of NSCLC could be
detected 24 h after administration, suggesting that miR-638
expression is increased at an early stage in response to cisplatin.
We also measured the serum miR-638 levels of 189 NSCLC
patients by qRT–PCR analysis and found that the 1-year
cumulative survival rate of patients with increased serum
miR-638 levels was 61.4% compared with 49.2% in patients
who had decreased serum miR-638 levels after one standard
chemotherapy cycle. Survival analyses further indicated that
NSCLC patients with higher serum miR-638 expression after
chemotherapy had a longer mean survival time than those with
lower serum miR-638 expression. Serum expression patterns of
miR-638 after chemotherapy were also associated with lymph
node metastasis, suggesting that expression patterns may be
inversely related to cell invasion in NSCLC. In addition,
monitoring the dynamic changes in miR-638 expression before
and after chemotherapy in the sera of representative patients
demonstrated that those who had positive responses to
chemotherapy showed increased serum miR-638 levels,
whereas those who displayed stable or progressive disease
exhibited decreased serum miR-638 levels.
The value of miRNAs as prognostic tools has previously been
demonstrated.29–32 Indeed, as non-invasive biomarkers of
disease and therapy response, miRNAs could serve as prog-
nostic indicators in some solid tumors. For example, serum
miR-221 is closely related to ovarian cancer prognosis, and its
elevated expression indicates a poor prognosis.23 Additionally,
colorectal cancer patients with higher serum expression of
miR-92a have a poorer prognosis.22
It has been reported that miR-638 is down-regulated in
several types of cancer, including lung cancer. miR-638 is
dramatically down-regulated in gastric cancer tissues, and it has
been shown to inhibit the expression of cyclin D1 by inhibiting
specificity protein 2 (Sp2) expression, thus suppressing gastric
cancer cell proliferation.33 Downregulation of miR-638 expres-
sion has been confirmed in NSCLC tissues and is reported to
be involved in promoting the transformation of normal cells
into tumor cells.14 Moreover, downregulated miR-638 has been
shown to induce cell invasion and proliferation by regulating
SRY-box 2, which is related to epithelial-to-mesenchymal
transition in the development of NSCLC, and the effect is
reversed by high expression of miR-638 or silencing of SRY-
box 2.34 A similar functional role has also been found in
colorectal carcinoma cells.35 However, over-expression of
Table 2 Univariate and multivariate COX regression model analysis of overall survival in NSCLC patients
Univariate analysis Multivariate analysis
Variables HR 95% CI P-value HR 95% CI P-value
Age 1.014 0.984–1.044 0.366
Gender 0.908 0.415–1.986 0.809
Smoking 1.733 0.800–3.750 0.163
TNM stage 2.017 0.686–5.934 0.202
Lymph node metastasis 6.035 2.041–17.845 0.001* 3.196 1.938–15.869 0.001*
miR-638 expression status 2.142 1.130–4.060 0.02* 2.258 1.031–3.456 0.04*
Abbreviations: HR, hazard ratio; CI, confidence interval; NSCLC, non-small cell lung cancer.
*Po0.05, n=183.
Figure 6 Expression levels of miR-638 at different time points
following chemotherapy. (a–d) Serum miR-638 expression levels in
four patients who received several cycles of chemotherapy were
monitored by qRT–PCR. A relative log2 (fold change) of 1 was
considered the initial miR-638 expression level before
chemotherapy.
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miR-638 in vascular smooth muscle cells has been shown to
inhibit cell proliferation and migration by targeting the NOR1
receptor,36 which might partially explain the correlation
between the increased expression of miR-638 and favorable
prognosis. In our previous study, over-expression of miR-638
in vitro induced apoptosis of lung cancer cells by regulating
P21-activated protein kinase. However, a clinically significant
link between levels of miR-638 in serum and NSCLC prognosis
has not been previously reported.
In conclusion, we have revealed that serum miR-638
expression levels varied in NSCLC patients after chemotherapy,
which was associated with NSCLC prognosis. More specifically,
upregulation of serum miR-638 was correlated with a favorable
prognosis for NSCLC patients. This is also the first study to
indicate that miR-638 expression patterns correlate with lymph
node metastasis and clinical outcome. Serum miR-638 is a
useful independent factor for NSCLC prognosis and could be
used as a potential prognostic biomarker for overall survival of
NSCLC patients. However, further studies are required to
explore the underlying molecular mechanisms of miR-638 in
lung cancer tumorigenesis and progression and its possible use
as a therapeutic target for NSCLC.
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